J&J adds atopic dermatitis bispecifics to pipeline with $850M Proteologix buy
并购临床1期抗体药物偶联物免疫疗法
Johnson & Johnson agreed to acquire Proteologix for $850 million in cash, picking up a portfolio of experimental bispecific antibodies with a focus on treating atopic dermatitis. The lead asset PX128, which targets IL-13 and TSLP, is set to enter Phase I testing for moderate-to-severe atopic dermatitis as well as moderate-to-severe asthma.
Proteologix's slate also includes the preclinical asset PX130 under development for moderate-to-severe atopic dermatitis. Like PX128, the compound also directed against IL-13, but is designed to block IL-22 as well in order to restore the skin barrier and prevent inflammation from environmental triggers, such as allergens. Both assets are designed for infrequent dosing intervals.
"We see an opportunity for best-in-disease efficacy for both PX128 and PX130 as each bispecific antibody targets two different combinations of disease driving pathways,” remarked David Lee, global immunology therapeutic area head at Johnson & Johnson Innovative Medicine. The transaction, which also includes an additional undisclosed milestone payment to Proteologix, is set to close mid-year.
For Johnson & Johnson, the acquisition represents a strengthening of its focus in immunology. After a relatively quiet period on the M&A front for its pharma business, the Proteologix deal also hints at a ramping up of the healthcare giant's deal-making efforts. Earlier this year, it bought antibody-drug conjugate developer Ambrx Biopharma for $2 billion, although industry watchers have suggested that Johnson & Johnson's next major move could be in the medical device space rather than innovative medicines.
The Proteologix purchase also sees Johnson & Johnson jockeying for position in the space for anti-TSLP antibodies. Just this week, Blackstone Life Sciences committed up to $300 million in newly launched biotech Uniquity Bio to support development of the anti-TSLP candidate solrikitug, while in January, GSK bought Aiolos Bio and its mid-stage anti-TSLP candidate AIO-001 for up to $1.4 billion. For more, see Spotlight On: A look at the anti-TSLP pipeline.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。